A Closer Look at Ruxolitinib’s Pediatric AD Approval with Nicole Harter, MD
Ascletis Presents Positive Phase 3 Data for Denifanstat in Moderate-to-Severe Acne
FDA Approval Brings New Non-Steroidal Option for Pediatric AD
Peter Lio, MD, at EADV 2025: Rethinking the Atopic Dermatitis Journey